Amgen, Hospira Battle Over Experts Ahead Of Patent Trial
By Vince Sullivan (June 28, 2017, 6:23 PM EDT) -- Pharmaceutical company Amgen Inc. sparred Wednesday in Delaware federal court with competitor Hospira Inc. over expert reports each side is hoping to use at a September patent infringment trial on Hospira's efforts to produce a biosimilar version of Amgen's anti-anemia drug Epogen.
During a hearing in Wilmington, attorneys for Amgen attempted to poke holes in the methodology used by Hospira's expert witness to calculate potential damages caused by Hospira's alleged infringement of U.S. Patent Numbers 5,756,349 and 5,856,298 through its biosimilar version of Epogen. The drug is used to treat anemia in dialysis patients.
Amgen attorney Julianne M. Hartzell of Marshall...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!